Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modified FOLFIRINOX in Advanced Urachal Cancer
NCT04611724Phase 2Unknown
- Sponsor
- Asan Medical Center
- Start
- Dec 2020
- Primary completion
- Dec 2023
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin, folinic acid, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab and fluorouracil in urachal cancer, sponsored by Asan Medical Center. Primary endpoint: Objective Response Rate at 2 years. Status: unknown.
02
Drugs
oxaliplatinfolinic acidirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabfluorouracil
03
Conditions
urachal cancer
Beyond the preview
Go deeper on NCT04611724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04611724.